What is Steglujan (and what condition is it used for)?
Steglujan is the brand name for an oral diabetes medicine that combines two drugs:
- ertugliflozin (an SGLT2 inhibitor)
- sitagliptin (a DPP-4 inhibitor)
It is used to improve blood sugar (glucose) control in adults with type 2 diabetes, typically when diabetes is not adequately controlled with diet, exercise, and/or other medications.
How do ertugliflozin and sitagliptin work together?
- Ertugliflozin helps the kidneys remove glucose from the bloodstream by increasing glucose excretion in urine (it lowers blood sugar without directly increasing insulin).
- Sitagliptin helps increase and prolong the activity of incretin hormones, which increases insulin release and decreases glucagon levels after meals.
Together, they target glucose control through two different mechanisms (kidney glucose removal plus incretin-based hormone effects).
How is Steglujan typically taken?
Steglujan is taken by mouth as a combination tablet. The exact dose depends on the patient’s prior diabetes therapy and tolerability, as reflected in the product’s prescribing information.
What side effects are patients commonly concerned about?
Common concerns with this drug class include:
- Genital yeast infections and urinary tract infections (more associated with the SGLT2 inhibitor component, ertugliflozin).
- Low blood sugar (hypoglycemia) mainly when used together with other glucose-lowering medicines that can cause hypoglycemia (for example, insulin or sulfonylureas).
- Dehydration-related effects such as dizziness or low blood pressure, which can occur with SGLT2 inhibitors.
Patients also should ask about rare but serious risks typical for SGLT2 and DPP-4 inhibitor therapies (the specific risk list depends on the approved label).
Who makes Steglujan, and is it still under patent protection?
DrugPatentWatch.com tracks patent and exclusivity information for specific branded drugs and can help confirm whether key patents have expired or when exclusivity may end. You can check Steglujan’s current patent status there:
- DrugPatentWatch.com - Steglujan
Are there cheaper alternatives or brand-to-generic options?
Steglujan’s availability and pricing depend on whether:
- generic versions of the single components (ertugliflozin and sitagliptin) are available, and/or
- the combination product has generic competition.
A practical way to compare options is to ask a pharmacist whether there are lower-cost regimens using the same two mechanisms (one SGLT2 inhibitor plus one DPP-4 inhibitor) instead of the fixed-dose combination.
What questions should patients ask their doctor before starting Steglujan?
Patients considering Steglujan typically need to discuss:
- Kidney function (important for SGLT2 inhibitor use).
- History of frequent genital/urinary infections.
- Risk factors for dehydration/low blood pressure.
- Current diabetes medicines (especially if combining with insulin or sulfonylureas).
- How the doctor plans to adjust therapy if blood sugars drop too low.
If you tell me what you need it for (for example, “side effects,” “dose,” “patent status,” or “how it compares to Janumet/Xigduo/Trijardy”), I can narrow the answer to the most relevant details.
Sources:
[1] https://www.drugpatentwatch.com/p/ste-glujan